Market News

Veritas Investment Management Llp Lifted Cvs Caremark (CVS) Stake; Last Week Vitamin Shoppe, Inc. (VSI) Coverage

Veritas Investment Management Llp increased Cvs Caremark Corp (CVS) stake by 8.14% reported in 2017Q3 SEC filing. Veritas Investment Management Llp acquired 53,785 shares as Cvs Caremark Corp (CVS)’s stock declined 4.23%. The Veritas Investment Management Llp holds 714,708 shares with $58.12 million value, up from 660,923 last quarter. Cvs Caremark Corp now has $72.84 billion valuation. The stock increased 2.00% or $1.41 during the last trading session, reaching $71.9. About 6.47 million shares traded. CVS Health Corporation (NYSE:CVS) has declined 24.40% since February 18, 2017 and is downtrending. It has underperformed by 41.10% the S&P500.

Among 11 analysts covering Vitamin Shoppe (NYSE:VSI), 1 have Buy rating, 2 Sell and 8 Hold. Therefore 9% are positive. Vitamin Shoppe had 26 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Barclays Capital on Thursday, August 10 with “Equal-Weight”. As per Thursday, August 6, the company rating was maintained by Deutsche Bank. Morgan Stanley maintained it with “Equal-Weight” rating and $4 target in Thursday, November 9 report. Robert W. Baird maintained it with “Hold” rating and $7.0 target in Friday, September 15 report. The rating was downgraded by Morgan Stanley on Thursday, November 3 to “Equal-Weight”. On Thursday, August 10 the stock rating was maintained by Deutsche Bank with “Hold”. The rating was downgraded by Goldman Sachs on Thursday, January 19 to “Sell”. Zacks upgraded the stock to “Sell” rating in Saturday, August 8 report. The stock of Vitamin Shoppe, Inc. (NYSE:VSI) earned “Underweight” rating by Morgan Stanley on Tuesday, January 17. Barclays Capital initiated the stock with “Equal Weight” rating in Friday, September 23 report. See Vitamin Shoppe, Inc. (NYSE:VSI) latest ratings:

09/11/2017 Broker: Barclays Capital Rating: Equal-Weight Old Target: $6 New Target: $3 Maintain
09/11/2017 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $7.5 New Target: $4 Maintain
02/10/2017 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $8 New Target: $7.5 Maintain
15/09/2017 Broker: Robert W. Baird Rating: Hold New Target: $7.0 Maintain

Among 25 analysts covering CVS Health (NYSE:CVS), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. CVS Health had 72 analyst reports since July 22, 2015 according to SRatingsIntel. The stock has “Hold” rating by Deutsche Bank on Wednesday, July 22. Robert W. Baird maintained it with “Hold” rating and $81.0 target in Thursday, January 4 report. The firm earned “Hold” rating on Friday, September 8 by Needham. The firm has “Buy” rating by Needham given on Tuesday, January 30. On Monday, September 25 the stock rating was maintained by Robert W. Baird with “Hold”. The firm earned “Outperform” rating on Friday, February 9 by Leerink Swann. RBC Capital Markets maintained the stock with “Buy” rating in Monday, December 4 report. Cowen & Co maintained the stock with “Buy” rating in Tuesday, June 13 report. Mizuho maintained CVS Health Corporation (NYSE:CVS) on Thursday, June 23 with “Buy” rating. On Wednesday, August 19 the stock rating was reinitiated by Evercore with “Buy”.

Investors sentiment decreased to 0.88 in Q3 2017. Its down 0.04, from 0.92 in 2017Q2. It dived, as 60 investors sold CVS shares while 571 reduced holdings. 88 funds opened positions while 466 raised stakes. 801.45 million shares or 0.31% less from 803.96 million shares in 2017Q2 were reported. Rockland Tru holds 172,241 shares or 2.09% of its portfolio. Live Your Vision Limited Liability Corporation, a Pennsylvania-based fund reported 125 shares. Ballentine Partners Lc reported 8,795 shares. Newman Dignan & Sheerar holds 26,023 shares or 1.13% of its portfolio. Jnba Advisors has 0.11% invested in CVS Health Corporation (NYSE:CVS) for 5,999 shares. Moreover, Reliance Trust Of Delaware has 0.54% invested in CVS Health Corporation (NYSE:CVS) for 44,008 shares. Cleararc Capital holds 0.32% of its portfolio in CVS Health Corporation (NYSE:CVS) for 26,148 shares. Cibc World Markets Inc reported 0.05% in CVS Health Corporation (NYSE:CVS). British Columbia Investment Mngmt holds 0.27% of its portfolio in CVS Health Corporation (NYSE:CVS) for 427,752 shares. Woodstock invested in 114,961 shares or 1.78% of the stock. Livingston Asset Co (Operating As Southport Cap Management) owns 48,254 shares for 1.67% of their portfolio. Bellecapital Ltd owns 28,477 shares or 2.73% of their US portfolio. Next Fincl Group Inc Incorporated Inc has invested 0.23% in CVS Health Corporation (NYSE:CVS). Oppenheimer Asset Management stated it has 25,367 shares. Moreover, Hamel has 0.71% invested in CVS Health Corporation (NYSE:CVS) for 17,850 shares.

Since August 16, 2017, it had 0 insider purchases, and 6 sales for $58.12 million activity. Moriarty Thomas M had sold 90,267 shares worth $7.19 million on Monday, September 11. 85,743 CVS Health Corporation (NYSE:CVS) shares with value of $7.13 million were sold by Roberts Jonathan C. Denton David M had sold 237,078 shares worth $18.88 million on Monday, September 11. Another trade for 39,340 shares valued at $3.22M was sold by Foulkes Helena. 2,500 shares were sold by SWIFT RICHARD J, worth $199,050 on Wednesday, August 16. On Wednesday, August 23 MERLO LARRY J sold $20.03M worth of CVS Health Corporation (NYSE:CVS) or 241,150 shares.

Leave a Reply

Your email address will not be published. Required fields are marked *